

GLAXOSMITHKLINE PLC  
Form 6-K  
February 09, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 09 February 2017

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Philip Hampton
  - b) Position/status Non-Executive Chairman
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument
 

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction
 

Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.55	924.285
Aggregated information n/a (single transaction)	
  - d) Aggregated volume Price
  - e) Date of the transaction 2017-02-08
  - f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Professor Sir Roy Anderson
  - b) Position/status Independent Non-Executive Director
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£15.55	1,850.161
		n/a (single transaction)	

d) Aggregated information  
Aggregated volume Price

e)	Date of the transaction	2017-02-08
f)	Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr Vindi Banga
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
----	---	--	--

b) Nature of the transaction

Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.55	271.263
n/a (single transaction)	

d) Aggregated information  
Aggregated volume Price

e) Date of the transaction 2017-02-08

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr Vivienne Cox
b) Position/status	Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
------------------------------	--

c) Price(s) and volume(s)

Price(s)	Volume(s)
----------	-----------



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms Judy Lewent
- b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053
- b) Nature of the transaction Acquisition of notional ADSs following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| \$39.46                  | 626.140   |
| n/a (single transaction) |           |
- d) Aggregated information  
Aggregated volume Price
- e) Date of the transaction 2017-02-08
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr Urs Rohner
- b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793  
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| £15.55                   | 186.803   |
| n/a (single transaction) |           |
- d) Aggregated information  
Aggregated volume Price
- e) Date of the transaction 2017-02-08  
f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 09, 2017

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

